Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Friday, Jan. 30, 2015, 44 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $300.00 to $7,196,200.00.

Highlighted Stocks Traded by Insiders:

Mednax (MD) - FREE Research Report

Hawk William C, who is COO American Anesthesiology at Mednax, sold 3,598 shares at $68.50 on Jan. 30, 2015. Following this transaction, the COO American Anesthesiology owned 11,550 shares meaning that the stake was reduced by 23.75% with the 3,598-share transaction.

The shares most recently traded at $67.74, down $0.76, or 1.12% since the insider transaction. Historical insider transactions for Mednax go as follows:

  • 4-Week # shares sold: 8,800
  • 12-Week # shares sold: 8,800
  • 24-Week # shares sold: 8,800

The average volume for Mednax has been 622,000 shares per day over the past 30 days. Mednax has a market cap of $6.9 billion and is part of the health care sector and health services industry. Shares are up 2.69% year-to-date as of the close of trading on Friday.

MEDNAX, Inc., together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, and other pediatric subspecialties care physician services in the United States and Puerto Rico. The company has a P/E ratio of 21.6. Currently, there are 9 analysts who rate Mednax a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MD - FREE

TheStreet Quant Ratings

rates Mednax as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, growth in earnings per share and increase in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full

Mednax Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Southwest Bancorp (OKSB) - FREE Research Report

Lanie Larry J, who is Director at Southwest Bancorp, bought 2,500 shares at $15.31 on Jan. 30, 2015. Following this transaction, the Director owned 9,250 shares meaning that the stake was boosted by 37.04% with the 2,500-share transaction.

The shares most recently traded at $15.51, up $0.20, or 1.29% since the insider transaction. Historical insider transactions for Southwest Bancorp go as follows:

  • 4-Week # shares bought: 8,000
  • 4-Week # shares sold: 4,000
  • 12-Week # shares bought: 8,000
  • 12-Week # shares sold: 4,000
  • 24-Week # shares bought: 8,000
  • 24-Week # shares sold: 4,000

The average volume for Southwest Bancorp has been 75,900 shares per day over the past 30 days. Southwest Bancorp has a market cap of $299.0 million and is part of the financial sector and banking industry. Shares are down 12.1% year-to-date as of the close of trading on Friday.

Southwest Bancorp, Inc. operates as the bank holding company for the Bank SNB, National Association that provides commercial and consumer banking services in Oklahoma, Texas, and Kansas. The stock currently has a dividend yield of 1.56%. The company has a P/E ratio of 13.7. Currently, there are 3 analysts who rate Southwest Bancorp a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on OKSB - FREE

TheStreet Quant Ratings

rates Southwest Bancorp as a

hold

. The company's strengths can be seen in multiple areas, such as its revenue growth, expanding profit margins and notable return on equity. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income, a generally disappointing performance in the stock itself and feeble growth in the company's earnings per share. Get the full

Southwest Bancorp Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Uroplasty (UPI) - FREE Research Report

Reynolds Brett, who is Senior Vice President and CFO at Uroplasty, bought 5,000 shares at $1.32 on Jan. 30, 2015. Following this transaction, the Senior Vice President and CFO owned 138,000 shares meaning that the stake was boosted by 3.76% with the 5,000-share transaction.

The shares most recently traded at $1.26, down $0.06, or 4.56% since the insider transaction. Historical insider transactions for Uroplasty go as follows:

  • 4-Week # shares bought: 10,000
  • 4-Week # shares sold: 38,000
  • 12-Week # shares bought: 10,000
  • 12-Week # shares sold: 38,000
  • 24-Week # shares bought: 10,000
  • 24-Week # shares sold: 38,000

The average volume for Uroplasty has been 165,500 shares per day over the past 30 days. Uroplasty has a market cap of $28.1 million and is part of the health care sector and health services industry. Shares are down 40.29% year-to-date as of the close of trading on Friday.

Uroplasty, Inc., a medical device company, develops, manufactures, and markets products for the treatment of voiding dysfunctions primarily in the United States. Currently, there is 1 analyst who rates Uroplasty a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on UPI - FREE

TheStreet Quant Ratings

rates Uroplasty as a

sell

. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity, weak operating cash flow and generally disappointing historical performance in the stock itself. Get the full

Uroplasty Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null